- Matchmaker & Negotiator for Commercial Projects in Health Care, Agriculture and Food Products;- Business Development Consultant for Pharmalex Brazil (subsidiary of Cencora, Inc.)- Matchmaker for Roolife Group (Australia) - Consumer Products / 2022-23- Brazilian agent for SAAM Deutschland GmbH - Pharmaceuticals/Fertilizers / 2022-...;- Brazilian agent for USPharma (USA) - Pharmaceuticals / 2020 - 2022- Brazilian intermediator for Buddy Healthcare (Finland) - Digital Patient… Show more - Matchmaker & Negotiator for Commercial Projects in Health Care, Agriculture and Food Products;- Business Development Consultant for Pharmalex Brazil (subsidiary of Cencora, Inc.)- Matchmaker for Roolife Group (Australia) - Consumer Products / 2022-23- Brazilian agent for SAAM Deutschland GmbH - Pharmaceuticals/Fertilizers / 2022-...;- Brazilian agent for USPharma (USA) - Pharmaceuticals / 2020 - 2022- Brazilian intermediator for Buddy Healthcare (Finland) - Digital Patient Platform / 2017 - 2021;- Brazilian agent for trAIDe GmbH (Germany) - International Business Development / 2015 -2018; - Brazilian agent for P.L.I. (Poland) - Digital Learning Programs / 2014 - 2017;- Brazilian agent for Pharmacare (Australia) - Nutraceuticals/Supplements / 2013 - 2015;- Brazilian agent for GenericPharma2.0 - International Business Develoment/ 2011 - 2013;- Co-Author of the Brazilian Generic Industry Guide 2012, via GP20; - Start-up of K.W. Consultoria (formerly Medixx Solutions);- Consultant for Gerson Lehrman Group, Atheneum and HealthAdvances;- Pharma matchmaking services for Wilson Sonsini Goodrich & Rosati; - M & A matchmaking services for Lincoln International and FC Partners; - Start-up evaluations and prospection for patient compliance devices; - Prospecting and intermediation of business opportunities with haemoderivates, hyaluronic acid, OTC products, prescription drugs;- Consulting and intermediation of probiotic product licenses for Christian Hansen (Denmark);- Consulting about Brazilian API market for Thomson Group (USA);SPECIAL PROJECTS AND RESULTS:- Selected export projects into Mexico (health food products).- Start-up of a commercial silviculture project with non-native species.- Intermediation of generics project for Grupo EMS;- Development of a differentiated supply and distribution model for immunoglobulins.- Consulting about pharma acquisitions (generics) for a large investment bank. Show less

- Start-up of a commercial generics operation in Brazil;- Strategic, commercial and financial planning and management of the operation;- Planning and strategic management of new product portfolios, generics as well as prescription products;- Coordination of galenic development projects for generic and prescription formulations;- Negotiation of licensing contracts and supply agreements for generics, prescription products and API, on national and international level;-… Show more - Start-up of a commercial generics operation in Brazil;- Strategic, commercial and financial planning and management of the operation;- Planning and strategic management of new product portfolios, generics as well as prescription products;- Coordination of galenic development projects for generic and prescription formulations;- Negotiation of licensing contracts and supply agreements for generics, prescription products and API, on national and international level;- Founding member of PROGENERICOS - the Brazilian Generics Association.RESULTS:- Annual generics sales volume by 2005: 35 million reais, with an EBIT of 11%;- Generics business: Break-even by third full year of operation;- Launch of 30 molecules between 2000 and 2006; - Creation of a specific marketing and sales structure for the generics business;- Planning and participation in government tenders, with sales of six million reais in 2004;- Intermediation of an export project to the corporate subsidiary in Canada, with sales of 300 million tablets between 2004 and 2005, for a value of three million dollars and increase of factory production volume by 20%; - Negotiation of out-licensing contracts for metformin and 5 additional molecules to local partners, generating sales of five million reais in 2005; - Launch of CLINFAR (sinvastatin) and REFLAX (cefaclor) in 2000 for the Pharma Division, with sales of two million reais in 2005;- Development and pre-launch activities for e LOSARTION (losartan) and DICLIN (CPA+ EE) for the Pharma Division;- Negotiation of in-licensing contracts for an additional 60+ molecules, coming from India, Spain, Australia, Canada, Ireland and France;- Planning and development coordination of a portfolio of generic products for the Latin American subsidiaries; Show less

- Structuring of a Business Development Department and the planning process for a new product portfolio; - Prospection and negotiation of licensing opportunities and new products for the Pharma, OTC and Veterinary Divisions; - Coordination of the galenic development of prescription products for CNS, respiratory diseases and other strategic indications; - Administration of international commercial partnerships; - Negotiation of veterinary active ingredients;- Business… Show more - Structuring of a Business Development Department and the planning process for a new product portfolio; - Prospection and negotiation of licensing opportunities and new products for the Pharma, OTC and Veterinary Divisions; - Coordination of the galenic development of prescription products for CNS, respiratory diseases and other strategic indications; - Administration of international commercial partnerships; - Negotiation of veterinary active ingredients;- Business assessor to the president-owner of the company;- Liaison to consulting projects on market intelligence, strategic evaluation of the ongoing pharma business and prospective opportunities in the oncology and gynecology segments. RESULTS:- Planning of a complementary product portfolio for the CNS business unit;- Development of FLUIR (formoterol) for asthma treatment. Launched in 2001, with annual sales of 20 million dollars by 2009; - Prospection and development of APRAZ (alprazolam). Launched in 2000;- Development of PREDSIM (prednisolone). Launched in 2000; - Purchase cost reduction of 30% for veterinary ivermectin, resulting in an economy of two million dollars between 1998 and 1999; - Creation of an international supplier network for API and formulations (Italy, India and Switzerland, among others). Show less

- Start-up of a business unit for CNS products;- Planning and strategic management of marketing, sales, product portfolio and P&L of the business unit, in close coordination with the company presidency and commercial partners; RESULTS:- Annual sales volume of eight million dollars by 1997, with a contribution margin of 65%; - Launch of brands CIPRAMIL (citalopram), LIORAM (zolpidem), and CLOPIXOL (zuclopentixol);- Hiring of a specific CNS sales and marketing team with 35… Show more - Start-up of a business unit for CNS products;- Planning and strategic management of marketing, sales, product portfolio and P&L of the business unit, in close coordination with the company presidency and commercial partners; RESULTS:- Annual sales volume of eight million dollars by 1997, with a contribution margin of 65%; - Launch of brands CIPRAMIL (citalopram), LIORAM (zolpidem), and CLOPIXOL (zuclopentixol);- Hiring of a specific CNS sales and marketing team with 35 employees;- Development and implementation of a CNS-specific training program for product management and technical promotion to physicians; - Development of a monitoring system for sales force efficiency, resulting in a 150% increase of prescriptions within 6 months; - Redirectioning of physical product sales, resulting in sales growth of 150% within 6 months; - Negotiation of extension of licensing contract for CIPRAMIL, guaranteeing 3 additional years of product exclusivity; - Negotiation of a 5-year licensing contract for CLOPIXOL;- Negotiation of a licensing contract for a second brand of STILNOX in Brazil (->LIORAM).ADDITIONAL, as Project Manager 1994/95:- Launch of the antibiotic ROTRAM (roxithromycine) in 1994, with annual net sales of nine million dollars by 1998. Show less

Products: INTRON A (interferon alpha 2-b); EULEXIN (flutamide).Overall marketing planning and execution for these products.

Products: PHEBO Deodorants; METAMUCIL (plantago o.).

Products: FLOXACIN (norfloxacin), CHIBRET Ohthalmological line.Overall marketing planning and execution for these products.Launch of CHIBROXIN (ophthalmic norfloxacin).